Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical produ...
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin’s lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer’s disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.
On March 31, 2026, Eli Lilly entered a definitive agreement to acquire Centessa Pharmaceuticals for $38 per share in cash plus a contingent value right worth up to $9 per share, representing a potential total equity value of approximately $7.8 billion. The transaction would add Centessa’s orexin receptor 2 agonist pipeline and expand Lilly into sleep medicine.
Roadmap referenceOn April 1, 2026, the United States Food and Drug Administration approved Foundayo, orforglipron, for chronic weight management in adults with obesity or adults with overweight and at least one related medical condition. The approval gave Lilly a once daily oral GLP 1 treatment that can be taken without food or water restrictions and added a second obesity medicine to its portfolio.
Roadmap referenceThe FDA approved supplemental applications adding an indication for Mounjaro to reduce the risk of major adverse cardiovascular events, including cardiovascular death, nonfatal myocardial infarction or nonfatal stroke, in adults with type 2 diabetes who are at high risk for these events.
Roadmap referenceChairman, President & CEO
Company leadership profile.
Chairman Emeritus
Company leadership profile.
Independent Director
Company leadership profile.
Lead Independent Director
Company leadership profile.
Independent Director
Company leadership profile.
Independent Director
Company leadership profile.
Independent Director
Company leadership profile.
Independent Director
Company leadership profile.
Independent Director
Company leadership profile.
Independent Director
Company leadership profile.
Independent Director
Company leadership profile.
Independent Director
Company leadership profile.
Independent Director
Company leadership profile.
3 experts evaluated Eli Lilly.
Explore the public profiles of experts who have evaluated this project.
Orbitrum Academy
